Sorafenib increases cytochrome P450 lipid metabolites in patient with hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is a leading cause of cancer death, and medical treatment options are limited. The multikinase inhibitor sorafenib was the first approved drug widely used for systemic therapy in advanced HCC. Sorafenib might affect polyunsaturated fatty acids (PUFA)-derived epoxygenat...
Saved in:
Main Authors: | , , , , , , , , , , , , , , |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2023-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Internet
Connect to this object online.3rd Floor Main Library
Call Number: |
A1234.567 |
---|---|
Copy 1 | Available |